Mdxhealth (MDXH) Q4 2025 earnings review
Bought Growth, Shrank the Core
Mdxhealth finished FY25 at the bottom edge of its $108-$110M revenue guidance, delivering $107.9M. While Q4 top-line growth looks solid at +19% YoY, the quality of that revenue has fundamentally shifted. The newly acquired ExoDx test drove a massive 128% surge in liquid test volumes, masking a sudden and concerning 5% contraction in the company's core, high-margin tissue testing business. Furthermore, the company's celebrated pivot to profitability was short-lived: after posting a positive Adjusted EBITDA in Q3, heavy integration costs and headcount expansion pushed Q4 Adjusted EBITDA back into the red at -$2.1M. Management is betting the farm on ExoDx to drive 27-30% growth in 2026, but organic decay in the legacy business requires immediate investor scrutiny.
🐂 Bull Case
The ExoDx acquisition is working exactly as advertised on the volume front. Liquid-based test volumes accelerated violently, up 128% YoY in Q4 to 27,486 tests. This positions the company perfectly for its ambitious 2026 growth targets.
Management confidently guided to $137-$140M in FY26 revenue. This implies growth accelerating to 27-30%, a significant step up from FY25's 20% pace.
🐻 Bear Case
Tissue-based test volumes (Confirm mdx and GPS) dropped 5% YoY in Q4. This is a severe reversal from the +41% growth seen in Q1 and directly contradicts management's narrative of a bulletproof, highly productive sales channel.
The company achieved positive Adjusted EBITDA in Q3, but gave it all back in Q4. Operating expenses surged 19% to integrate the new acquisition, showing that buying top-line growth is coming at a steep bottom-line cost.
⚖️ Verdict: ⚪
Neutral. The ExoDx acquisition successfully bought the company a new growth engine, but the simultaneous organic contraction in the higher-margin tissue business is a glaring red flag. 2026 targets are ambitious, but execution risk is peaking.
Key Themes
Sudden Reversal in Core Tissue Volumes
A critical red flag emerged in Q4: Tissue-based test volumes (Confirm mdx and GPS) fell 5% YoY to 11,201. This represents a violent deceleration and reversal from earlier in the year (+41% YoY in Q1, +18% in Q3). Because tissue tests historically command higher margins and made up ~80% of revenue, any organic decay here directly contradicts management's prior claims of 'consistent, disciplined execution.' The sales force appears distracted by the new ExoDx integration.
Profitability Trajectory Reverses
After a celebrated milestone of +$1.0M Adjusted EBITDA in Q3, profitability reversed course. Q4 Adjusted EBITDA fell to -$2.1M (a 53% wider loss YoY). This was driven by a 19% spike in operating expenses ($23.9M), as the company absorbed ExoDx headcount and acquisition-related costs. The promise of operating leverage has been temporarily broken.
Macro Headwinds: Biopsy Patient Flow Slowdown
Management previously noted a 'patient flow directed slowdown in the number of biopsies' during Q3. The Q4 tissue volume contraction (-5%) suggests this macro headwind has worsened, physically limiting the addressable market for the Confirm mdx test despite the company's expanded sales presence.
ExoDx Acquisition Ignites Liquid Portfolio
The integration of the ExoDx prostate test is aggressively accelerating the liquid-based portfolio. Liquid test volumes surged 128% YoY in Q4 (up from 65% growth in Q3). By rapidly migrating customers to this newly acquired asset, MDxHealth is successfully creating a second powerful revenue vertical to complement its tissue business.
Sales Force Expansion to Capture Synergies
To execute the cross-selling playbook between legacy tissue tests and the new ExoDx liquid test, the company expanded its direct sales force from 50 to 60 representatives and redrew its territories from 6 to 8 regions. If productivity per rep can return to historical averages, this larger footprint will be the primary driver of the guided 27-30% revenue growth in FY26.
Product Consolidation: Replacing Select mdx with ExoDx
Management is forcing technological evolution within its customer base by actively sun-setting the legacy Select mdx test and transitioning providers to the superior ExoDx assay. They have also completely shelved their planned Germline product to focus all R&D and commercial bandwidth on scaling the ExoDx innovation.
Other KPIs
Stable. Gross margin expanded slightly YoY from 62.7%, but decelerated sequentially from 65.2% in Q3. This sequential compression is likely due to the aggressive product mix shift toward liquid-based tests, which generally carry slightly different margin profiles than the legacy tissue business.
Reversing. Cash dropped significantly from $46.8M at the end of 2024. The massive burn over the year was primarily driven by the $28.0M earn-out payment made to Exact Sciences in H1 2025 for the GPS acquisition, alongside integration costs for ExoDx. Liquidity requires monitoring as debt stands at over $76M.
Guidance
Accelerating. This implies 27% to 30% YoY growth, a significant acceleration from the 20% growth achieved in FY25. Management is clearly confident that the combined urology menu (ExoDx + GPS + Confirm) will unlock massive cross-selling synergies across their newly expanded sales force.
Accelerating. Despite the Q4 margin compression (-7.1% margin), management expects improved productivity and operating leverage to drive the business to a 10% Adjusted EBITDA margin by the end of 2026. This implies heavy front-loaded integration costs in H1 26, followed by steep operating leverage in H2 26.
Key Questions
The Tissue Contraction
Tissue volumes dropped 5% YoY in Q4 after growing 18% in Q3 and 41% in Q1. How much of this was due to macro biopsy slowdowns versus sales force distraction from the ExoDx integration?
OpEx Run Rate
Operating expenses jumped to almost $24M this quarter. Is this the new structural baseline moving forward with 60 reps, or were there significant one-time ExoDx integration costs buried in that number?
Margin Mix Shift
As liquid-based volumes explode (+128%) and tissue volumes contract, what is the blended gross margin expectation for FY26? Can the company maintain its 64-65% profile with this new product mix?